Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.
- Potential 510(k) pathway identified for Felix
- FDA Pre-Submission engagement to test proposed predicate and evidence
- Formal submission targeted for Q1 CY2027
- US IVF market estimated at US$5.9 billion
- Repeat orders reported from Italy, the UK and MENA
Potential 510(k) pathway replaces De Novo plan
Memphasys Limited (ASX:MEM) has identified what could be a quicker route into the US fertility market for its Felix Sperm Separation System, after finding a legally marketed medical device it believes may serve as a regulatory predicate. That could allow Felix to pursue the FDA’s established 510(k) clearance pathway rather than the De Novo classification process previously contemplated.
The distinction matters, but the route is not yet secured. A 510(k) application would require Memphasys to demonstrate substantial equivalence to the proposed predicate, and the FDA has not yet confirmed that the device is suitable. The company’s next step is a Pre-Submission, or Q-Submission, engagement designed to obtain feedback on the predicate, regulatory strategy, testing requirements and supporting evidence.
FDA feedback precedes planned 2027 submission
Memphasys is targeting a formal 510(k) submission in Q1 CY2027, subject to the outcome of its FDA engagement and any additional work requested. The announcement does not provide an expected submission cost, approval probability or timetable for a regulatory decision, leaving the proposed pathway at an early but potentially important stage.
The commercial prize is substantial. Memphasys cites an estimated US IVF market of approximately US$5.9 billion in 2025, representing about 20% of global IVF revenue. It also points to 435,426 assisted reproductive technology cycles reported across 457 US clinics in 2022, alongside an estimate of roughly 500 clinics providing ART services. Those figures are company-cited market data rather than a forecast of Felix sales.
Existing markets remain the immediate test
Memphasys says the US regulatory programme will be ringfenced and pursued in parallel with its current commercialisation efforts across Europe, Australia and New Zealand, Asia and MENA. The company’s stated near-term focus is converting its existing distributor and clinic network into Felix cartridge sales, repeat orders and recurring revenue, rather than shifting management attention wholesale to the United States.
It reported additional repeat orders from existing partners and clinics in Italy, the UK and MENA, describing them as evidence of growing customer adoption, although it gave no order values, cartridge volumes or revenue figures. Executive Chairman David Tasker said the board’s reassessment had identified a “potentially faster and more direct pathway” while maintaining focus on adoption and revenue generation in the company’s established markets (ASX:MEM).
The next material checkpoint is the FDA’s response to the proposed predicate and evidence package. Until that feedback arrives, the US opportunity is best viewed as a possible reduction in regulatory complexity rather than a confirmed market-entry plan; the nearer commercial question is whether repeat orders translate into measurable cartridge volumes and cash generation.
Bottom Line?
The 510(k) proposal could improve the economics of US entry, but FDA acceptance of the predicate and evidence package remains the critical hurdle while existing-market sales provide the nearer test of execution.
Questions in the middle?
- Will the FDA accept Memphasys’s proposed predicate for the 510(k) pathway?
- What testing and evidence will the FDA require before a formal submission?
- Can repeat orders in current markets develop into disclosed cartridge growth and recurring revenue?